Synopsis: India’s largest drugmaker is eyeing a US pharma giant in a deal that could rewrite the rules of global pharma.
A pharma giant bets $12 billion on a foreign drugmaker – but the market isn’t convinced. India’s biggest pharma company is chasing a deal that could change everything – for better or worse. A $12 billion bid for a US-based specialty drug firm is now on the table, and the stakes couldn’t be higher.
With a market cap of Rs. 3,91,811 Cr, the shares of Sun Pharmaceutical Industries Ltd. are trading at a price of Rs. 1630 which is 4.8 percent down from its previous closing price of Rs. 1714.the stock is trading at an P/E ratio of 32.3.
India’s Pharma Giant Makes Its Boldest Move Yet
Sun Pharmaceutical Industries, India’s largest drugmaker, is reportedly preparing a binding bid worth $12 billion- roughly Rs.1.11 lakh crore, to acquire Organon & Co., a US-based pharma company spun off from Merck in 2021. If it goes through, this would be the biggest overseas acquisition ever attempted by an Indian pharma firm.
For years, Sun Pharma built its name on generics, affordable copies of branded drugs sold across 100+ countries. But that business is getting harder. Price erosion in the US, rising competition, and tighter regulations have squeezed margins industry-wide. The Organon deal signals a clear shift: away from generics, toward branded specialty drugs where pricing power is stronger and competition is thinner.
Organon is an attractive target for that reason. It focuses on women’s health, biosimilars, and established branded medicines, with a ready commercial presence across the US and Europe – a platform Sun Pharma would take years to build on its own.
But investors aren’t celebrating. The stock fell around 4% on the news. The worry is two-fold: Organon carries heavy debt, and a large portion of its revenue still comes from older drugs in slow decline. The fear is that Sun Pharma may be overpaying for a fading book of business.
Still, Sun Pharma has done this before. Its 2014 Ranbaxy acquisition was messy at first but eventually cemented its market leadership. If Organon follows a similar path, this Rs. 1.11 Lakh crore bet could redefine what an Indian pharma company looks like on the world stage.
About Sun Pharmaceutical Industries
Sun Pharmaceutical Industries Ltd, founded in 1983 by Dilip Shanghvi, is India’s largest and the world’s fourth-largest specialty generic pharmaceutical company. Headquartered in Mumbai, it sells branded and generic formulations, APIs, and specialty drugs across 100+ countries. Its key focus areas include dermatology, ophthalmology, oncology, and neurology.
Between December 2024 and December 2025, Sun Pharmaceutical Industries Ltd exhibited robust growth. Quarterly revenue climbed from ₹13,675 Cr to ₹15,521 Cr, a 13.5% increase driven by strong global sales. Simultaneously, net profit rose 16.1% to ₹3,381 Cr. This financial expansion was bolstered by improved operational efficiency, as operating margins expanded from 29% to 32%, reflecting the company’s successful strategic focus on high-margin specialty medications and consistent market leadership.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Bluechip stock falls 4% on $12 billion Organon acquisition deal as it worries investors appeared first on Trade Brains.